Stifel Financial Corp Increases Stock Holdings in Progyny, Inc. (NASDAQ:PGNY)

Stifel Financial Corp grew its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 48.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 71,736 shares of the company's stock after buying an additional 23,425 shares during the period. Stifel Financial Corp owned approximately 0.08% of Progyny worth $1,237,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Barclays PLC grew its position in Progyny by 530.4% in the 3rd quarter. Barclays PLC now owns 706,157 shares of the company's stock valued at $11,835,000 after purchasing an additional 594,140 shares during the period. Tidal Investments LLC grew its holdings in shares of Progyny by 67.7% during the third quarter. Tidal Investments LLC now owns 60,722 shares of the company's stock valued at $1,018,000 after buying an additional 24,507 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Progyny by 17.0% during the third quarter. Franklin Resources Inc. now owns 48,248 shares of the company's stock worth $759,000 after acquiring an additional 7,003 shares in the last quarter. GAMMA Investing LLC increased its holdings in Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock worth $28,000 after purchasing an additional 1,246 shares in the last quarter. Finally, Nordea Investment Management AB raised its position in Progyny by 5.8% in the 4th quarter. Nordea Investment Management AB now owns 185,042 shares of the company's stock valued at $3,175,000 after buying an additional 10,203 shares during the last quarter. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on PGNY. Canaccord Genuity Group upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research report on Friday, February 28th. Bank of America lifted their target price on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, February 11th. JPMorgan Chase & Co. raised their target price on Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Finally, BTIG Research raised shares of Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a report on Monday, March 31st. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $23.64.

Progyny Trading Down 9.3 %

Shares of NASDAQ:PGNY traded down $2.17 on Friday, reaching $21.20. 3,566,405 shares of the company traded hands, compared to its average volume of 1,722,248. The stock has a market capitalization of $1.82 billion, a P/E ratio of 36.55, a price-to-earnings-growth ratio of 2.39 and a beta of 1.37. The business's 50-day simple moving average is $21.95 and its 200 day simple moving average is $19.54. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $30.42.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.28). The firm had revenue of $324.04 million for the quarter, compared to analysts' expectations of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The business's revenue for the quarter was up 16.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.17 earnings per share. Sell-side analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.